NCT02819011View on ClinicalTrials.gov

OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

April 4, 2019

Conditions
Accidental FallsFall Due to Loss of EquilibriumHigh Risk of Falls Due to Mobility LimitationDiabetesArthritisCancerPeripheral Arterial DiseaseParkinson's DiseaseEnd Stage Renal Failure on Dialysis
Interventions
DEVICE

MBB AFO

Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO

OTHER

Control

Subjects will be provided with a pair of New Balance 813 shoes

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
collaborator

Orthotic Holdings, Inc.

INDUSTRY

lead

Bijan Najafi, PhD

OTHER

NCT02819011 - OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO | Biotech Hunter | Biotech Hunter